Milrinone Carinopharm

Milrinone, the active ingredient in Milrinone Carinopharm, is a phosphodiesterase‑3 inhibitor presented as an intravenous solution for intravenous use. It is employed to improve cardiac output in patients experiencing acute decompensated heart failure or cardiogenic shock.

GNH USA supplies Milrinone Carinopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The product complies with EU regulatory standards and is manufactured under GMP conditions for global distribution. It is available for bulk procurement to meet the needs of cardiac care units and intensive care facilities.

Milrinone is used as an inotropic agent in the management of severe cardiac conditions where contractility is compromised.

- Acute decompensated heart failure: provides positive inotropic support and vasodilation to increase cardiac output and relieve symptoms. - Cardiogenic shock: enhances myocardial contractility and reduces afterload, helping to stabilize systemic perfusion. - Low cardiac output syndrome after cardiac surgery: supports hemodynamics while the heart recovers, improving organ perfusion.

Milrinone may be associated with a range of adverse reactions, which are categorized by frequency and clinical significance.

Common Side Effects: - Hypotension: drop in blood pressure due to vasodilatory action. - Tachyarrhythmias: increased heart rate or irregular rhythm. - Headache: mild to moderate discomfort. - Nausea: gastrointestinal upset. - Flushing: transient skin redness. - Diarrhea: loose stools.

Serious or Rare Side Effects: - Severe hypotension: marked blood pressure fall requiring intervention. - Ventricular arrhythmias: life‑threatening heart rhythm disturbances. - Myocardial ischemia: reduced blood flow to heart muscle. - Thrombocytopenia: low platelet count. - Anaphylactic reactions: severe allergic response. - Hepatic dysfunction: elevated liver enzymes.

When using Milrinone, clinicians should observe several safety considerations to minimize risk.

- Monitor blood pressure: watch for hypotension and adjust infusion rate. - Observe cardiac rhythm: continuous ECG monitoring for arrhythmias. - Adjust dose in renal impairment: reduce infusion rate in patients with decreased clearance. - Use cautiously after recent myocardial infarction: risk of ischemia may be increased. - Avoid in severe aortic stenosis: fixed outflow obstruction can worsen hemodynamics. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Milrinone can interact with other medications, altering its efficacy or safety profile.

Major Interactions (Avoid): - Concurrent potent vasodilators (e.g., nitroprusside): may cause profound hypotension. - Other phosphodiesterase‑3 inhibitors: additive inotropic and vasodilatory effects increase risk of cardiovascular instability. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise plasma milrinone concentrations.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may blunt the inotropic response, requiring dose adjustments. - Digoxin: combined effect on cardiac contractility can increase risk of arrhythmias. - Diuretics: volume depletion can enhance hypotensive response.